| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3192 |
| Trial ID | NCT05556720 |
| Disease | Lymphoma | Chronic Lymphocytic Leukemia | Multiple Myeloma |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Pfizer Bivalent mRNA Vaccine|Moderna Bivalent mRNA Vaccine |
| Location approved | US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial |
| Year | 2022 |
| Country | Australia |
| Company sponsor | Bayside Health |
| Other ID(s) | 122.22 |
| Cohort1: People living with Human Immunodeficiency Virus (HIV) | |||||||||
|
|||||||||
| Cohort2: Solid Organ Transplant recipients | |||||||||
|
|||||||||
| Cohort3: People with Haematological Neoplasms (CLL, NHL, MM) | |||||||||
|
|||||||||